FDA grants premarket approval to Zoll’s hospital wearable defibrillator
The FDA granted premarket approval to Zoll Corporation’s hospital wearable defibrillator.
Zoll Corporation announced the approval in a news release on March 9.
The defibrillator is intended for patients at risk of ventricular tachycardia or ventricular fibrillation during their hospital stay.
If the device detects a life-threatening rhythm, it alerts patients before delivering a shock, which allows conscious patients to delay the shock, according to Zoll. The device is designed device delivers a shock within 60 seconds of detection.
Zoll Corporation said its hospital wearable defibrillator uses the same detection algorithm and defibrillation waveform as the company’s LifeVest wearable defibrillator.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.